EUVIMEDEUVIMED entdecken
Crossref

GLP‐1 receptor agonists in patients with MGUS: A real‐world propensity‐matched study

Anastasios Tentolouris iD, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Evangelos Terpos, Efstathios Kastritis, Ernesto Ruiz Duque, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou, Alexandros Briasoulis

European Journal of Clinical Investigation · 2026

DOI: 10.1111/eci.70140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2026. Verfasst von Anastasios Tentolouris und 8 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, Laiko Gen…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell disorder with potential progression to multiple myeloma (MM). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated potential anti‐neoplastic properties. This study evaluated the association between GLP‐1 RA use and clinical outcomes in individuals with MGUS and concurrent DM, overweight or obesity.

Methods

A retrospective cohort study was conducted using the TriNetX global health research network. Adults with MGUS and either DM or overweight/obesity were identified. Propensity score matching (1:1) was performed, resulting in two balanced cohorts. The primary outcome was progression‐free survival (PFS). Secondary outcomes included overall survival (OS), time to progression to multiple myeloma (MM) and major cardiovascular events, including myocardial infarction (MI), ischemic stroke, ischemic heart disease and heart failure (HF).

Results

Among 30,034 matched patients, 823 patients in the GLP‐1 RA group and 2317 in the control group progressed to symptomatic MM or died. GLP‐1 RA use was associated with significantly improved PFS [HR (95% CI): .63 (.58–.68)] and OS [HR (95% CI): .61 (.56–.66)]. A reduced risk of progression to symptomatic MM was also observed [HR (95% CI): .82 (.69–.98)]. GLP‐1 RA users had lower cumulative incidence of MI, HF, ischemic heart disease, and stroke; however, these differences were not confirmed in time‐to‐event analyses.

Conclusions

GLP‐1 RA therapy was associated with significantly improved PFS and OS in MGUS patients with metabolic comorbidities. While fewer cardiovascular events were observed, these findings were not statistically confirmed over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaHumansMaleFemaleRetrospective StudiesAgedMiddle AgedPropensity ScoreProgression-Free SurvivalObesityDisease ProgressionOverweightMyocardial InfarctionHeart FailureCardiovascular DiseasesDiabetes MellitusIschemic StrokeAged, 80 and over

Stichwörter der Autor:innen

GLP‐1 receptor agonistscardiovascular outcomesdiabetes mellitusmonoclonal gammopathy of undetermined significancemultiple myelomaobesity

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
  • Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.
  • Division of Cardiovascular Medicine, University of Iowa, Iowa City, Iowa, USA.
  • Department of Medicine, Korea University, Seoul, Korea.

ORCID-Profile: Anastasios Tentolouris

Zitieren

APA

Tentolouris, A., Ntanasis-Stathopoulos, I., Filippatos, C., Terpos, E., Kastritis, E., Duque, E. R., Dimopoulos, M. A., Gavriatopoulou, M., & Briasoulis, A. (2026). GLP‐1 receptor agonists in patients with MGUS: A real‐world propensity‐matched study. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70140

Vancouver

Tentolouris A, Ntanasis-Stathopoulos I, Filippatos C, Terpos E, Kastritis E, Duque ER, et al. GLP‐1 receptor agonists in patients with MGUS: A real‐world propensity‐matched study. European Journal of Clinical Investigation. 2026. doi:10.1111/eci.70140

BibTeX
@article{Tentolouris2026,
  author = {Tentolouris, Anastasios and Ntanasis-Stathopoulos, Ioannis and Filippatos, Charalampos and Terpos, Evangelos and Kastritis, Efstathios and Duque, Ernesto Ruiz and Dimopoulos, Meletios-Athanasios and Gavriatopoulou, Maria and Briasoulis, Alexandros},
  title = {GLP‐1 receptor agonists in patients with MGUS: A real‐world propensity‐matched study},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1111/eci.70140}
}
Kostenlos starten →